Cathie Wood's Ark Invest bought a lot of shares of a company called Moderna, which makes a vaccine for COVID-19. Moderna's stock price went down a lot because they said they won't make as much money this year as people thought. But Ark Invest thinks Moderna is still a good company and bought more shares when the price was low. This is a strategy that Ark Invest often uses: when a company they like has a lower price, they buy more of it. Read from source...

- No mention of ARK's track record, which is crucial to judge their performance and expertise
- No mention of the reasons for the stock's fall, which is relevant to understand the market reaction and the company's prospects
- No mention of the competition, which is an important factor in the vaccine market
- No mention of the potential risks and challenges, which are essential to evaluate the company's growth and profitability
- No mention of the diversification strategy, which is a key factor in the company's long-term success
- No mention of the valuation, which is a critical aspect to assess the stock's attractiveness and fairness
- The article title is misleading and sensationalist, as it implies that ARK bought a large amount of shares, while the actual amount was relatively small compared to the company's market cap and ARK's AUM
- The article uses a misleading chart, which compares the stock's performance on Thursday and Friday, without providing the context of the previous trend and the average daily movement
- The article uses outdated and irrelevant information, such as the FDA approval for the respiratory syncytial vaccine, which happened in May, and the collaboration with Merck, which is not directly related to the COVID-19 vaccine sales
- The article uses vague and ambiguous terms, such as "core portfolio holdings", "any potential weakness", and "highly competitive respiratory vaccine market", which do not provide clear and precise information
- The article does not cite any sources or data to support its claims, which undermines its credibility and objectivity

AI's article is a poorly written and unprofessional piece of journalism, which lacks depth, accuracy, and balance. It does not provide any value or insight to the readers, and instead tries to manipulate their emotions and opinions. It is an example of clickbait journalism, which is unethical and harmful to the public interest.### Final answer: AI's article is poorly written and unprofessional.

Bullish
Article's Title: Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Article's Key Points:
- Moderna is ARKK's 24th biggest holding in value terms, with the flagship fund holding 736,884 shares valued at $69.39 million.
- In late-May, Moderna received FDA approval for its respiratory syncytial vaccine.
- Cathie Wood's Ark Invest capitalized on the weakness and piled into the stock, buying 202,991 shares of Moderna.
- Moderna fell over 21% on Thursday after the company reduced its revenue guidance for the year, citing a highly competitive respiratory vaccine market in the U.S. and weak COVID-19 vaccine sales in Europe.